Clinical prognostic value of the SMYD2/3 as new epigenetic biomarkers in solid cancer patients: a systematic review and meta-analysis.

Razmi, Mahdieh; Yazdanpanah, Ayna; Etemad-Moghadam, Shahroo; Alaeddini, Mojgan; Angelini, Sabrina; Eini, Leila

Razmi, Mahdieh; Yazdanpanah, Ayna; Etemad-Moghadam, Shahroo; Alaeddini, Mojgan; Angelini, Sabrina; Eini, Leila.

Afiliación

Razmi M; Dental Research Center, Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Yazdanpanah A; Oncopathology Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Etemad-Moghadam S; Department of Tissue Engineering and Regenerative Medicine, Iran University of Medical Sciences, Tehran, Iran.
Alaeddini M; Dental Research Center, Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Angelini S; Dental Research Center, Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Eini L; Department of Pharmacy and Biotechnology (Fabit), University of Bologna, Bologna, Italy.

Expert Rev Mol Diagn ; : 1-15, 2022 Nov 17.

Article en En | MEDLINE | ID: mdl-36346387

Palabras clave

SMYD2 protein; SMYD3 protein; disease/cancer-specific survival; disease/relapse/progression-free survival; meta-analysis; overall survival

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Systematic_reviews Idioma: En Revista: Expert Rev Mol Diagn Asunto de la revista: BIOLOGIA MOLECULAR Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google